Overview

• Dentsply Sirona Q3 net sales of $904 mln slightly beat analyst expectations

• Adjusted EPS for Q3 missed analyst expectations, reflecting operational challenges

• Company launches Return-to-Growth action plan to improve performance over 24 months

Outlook

• Company revises FY25 net sales outlook to $3.6 bln-$3.7 bln

• Dentsply Sirona expects FY25 adjusted EPS to be about $1.60

• Company anticipates constant currency sales to decline 4%-5% YoY in FY25

Result Drivers

• BYTE AND ERP IMPACT - Q3 sales decline partly due to Byte impact and ERP pre-buy activities

• LOWER VOLUMES - Impairment charges driven by lower-than-expected volumes in equipment, implants, and prosthetics, particularly in the U.S.

• FOREIGN CURRENCY IMPACT - Foreign currency changes positively impacted Q3 2025 net sales by $28 mln

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for DENTSPLY SIRONA Inc is $15.00, about 15.9% above its November 5 closing price of $12.62

• The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 7 three months ago

Press Release: ID:nGNX7sPzzv

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)